Heather Torbic

Heather Torbic

Auto-generated profile, based on publicly available information

Heather Torbic

Department of Pharmacy, Cleveland Clinic, Cleveland, OH

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
APAnupol Panitchote
Anupol Panitchote
OMOmar Mehkri
Omar Mehkri
AHAndrei Hastings
Andrei Hastings
THTarik Hanane
Tarik Hanane
SDSevag Demirjian
Sevag Demirjian
ADAbhijit Duggal
Abhijit Duggal
Acute kidney injury (AKI) is the most frequent extra-pulmonary organ failure in acute respiratory distress syndrome (ARDS). The objective of this study was to assess the factors associated with the development and severity of AKI in patients with ARDS. This is a retrospective cohort study of ARDS patients without acute or chronic kidney disease prior to the onset of ARDS over a 7-year period (2010–2017). AKI and severity of AKI were defined according to the Kidney Disease Improving Global Outcomes 2012 guidelines. Of the 634 ARDS patients, 357 patients met study criteria. A total of 244 (68.3%) patients developed AKI after ARDS onset: 60 (24.6%) had stage I AKI, 66 (27%) had stage II AKI, and 118 (48.4%) had stage III AKI. The median time of AKI onset for stage I AKI was 2 days (interquartile range, 1.5–5.5) while stage II and III AKI was 4 days. On multivariable analysis, factors associated with development of AKI were age [subdistribution hazard ratio (SHR) 1.01, 95% confidence interval (CI) 1.00–1.02], SOFA score (SHR 1.16, 95%CI 1.12–1.21), a history of diabetes mellitus (DM) (SHR 1.42, 95%CI 1.07–1.89), and arterial pH on day 1 of ARDS (SHR per 0.1 units decrease was 1.18, 95%CI 1.05–1.32). In severity of AKI, stage I AKI was associated with age (SHR 1.03, 95%CI 1.01–1.05) and serum bicarbonate on day 1 of ARDS (SHR 1.07, 95%CI 1.02–1.13). Stage II AKI was associated with age (SHR 1.03, 95%CI 1.01–1.05), serum bicarbonate on day 1 (SHR 1.12, 95%CI 1.06–1.18), SOFA score (SHR 1.19, 95%CI 1.10–1.30), history of heart failure (SHR 3.71, 95%CI 1.63–8.46), and peak airway pressure (SHR 1.04, 95%CI 1.00–1.07). Stage III AKI was associated with a higher BMI (SHR 1.02, 95%CI 1.00–1.03), a history of DM (SHR 1.79, 95%CI 1.18–2.72), SOFA score (SHR 1.29, 95%CI 1.22–1.36), and arterial pH on day 1 (SHR per 0.1 units decrease was 1.25, 95%CI 1.05–1.49). Age, a higher severity of illness, a history of diabetes, and acidosis were associated with development of AKI in ARDS patients. Severity of AKI was further associated with BMI, history of heart failure, and peak airway pressure.

8 February 2018 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
GSGretchen L. Sacha
Gretchen L. Sacha
SLSimon W. Lam
Simon W. Lam
ADAbhijit Duggal
Abhijit Duggal
HTHeather Torbic
Heather Torbic
ARAnita J. Reddy
Anita J. Reddy
SBSeth R. Bauer
Seth R. Bauer

8 October 2019 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
SNShraddha Narechania
Shraddha Narechania
HTHeather Torbic
Heather Torbic
ATAdriano R. Tonelli
Adriano R. Tonelli
Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors in the management of this disease. Poor adherence to treatment is a common problem in PAH as it is in many chronic diseases. Management of medication interruptions is a challenge in patients with PAH that can lead to negative consequences. However, for most PAH-specific drugs, there are no clear guidelines on how to manage temporary or abrupt medication discontinuations. In this review, we summarized the available literature and provide suggestions on how to manage interruptions of PAH-specific therapies.

25 August 2020 in Respiratory Care
Verified
Journal Article
Closed access
PDF file
HTHeather Torbic
Heather Torbic
SKSudhir Krishnan
Sudhir Krishnan
MHMary Pat Harnegie
Mary Pat Harnegie
ADAbhijit Duggal
Abhijit Duggal
BACKGROUND: Studies evaluating neuromuscular blocking agents (NMBAs) in the management of ARDS have produced inconsistent results in terms of their effect on mortality. The purpose of this systematic review and meta-analysis was to evaluate differences in mortality comparing subjects with ARDS who received NMBA to those who received placebo or usual care. METHODS: We searched Ovid, MEDLINE, Embase, CINAHL, Cochrane, Scopus, and Web of Science for randomized controlled trials evaluating administration of NMBAs in subjects with ARDS. RESULTS: We included 6 studies ( N = 1,558 subjects) from 1,814 abstracts identified by our search strategy. The use of early, continuous-infusion NMBAs reduces the risk of short-term (ie, 21–28-d) mortality (relative risk 0.71 [95% CI 0.52–0.98], P = .030, I 2 = 60%) in subjects with ARDS but does not reduce the risk of long-term (ie, 90-d) mortality (relative risk 0.81 [95% CI 0.64–1.04], P = .10, I 2 = 54%). NMBAs decreased the risk of barotrauma (relative risk 0.55 [95% CI 0.35–0.85], P = .008, I 2 = 0%) and pneumothorax (relative risk 0.46 [95% CI 0.28–0.77], P = .003, I 2 = 0%) compared to control. CONCLUSIONS: In subjects with ARDS, early use of NMBAs improves oxygenation, reduces the incidence of ventilator-induced lung injury, and decreases 21–28-d mortality, but it does not improve 90-d mortality. NMBAs should be considered for select patients with moderate-to-severe ARDS for short durations.

1 February 2019 in Journal of Critical Care
Verified
Journal Article
Closed access
HTHeather Torbic
Heather Torbic
ADAbhijit Duggal
Abhijit Duggal

4 August 2020 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
PDF file
NQNicholas J. Quinn
Nicholas J. Quinn
BHBenjamin Hohlfelder
Benjamin Hohlfelder
MWMatthew R. Wanek
Matthew R. Wanek
ADAbhijit Duggal
Abhijit Duggal
HTHeather Torbic
Heather Torbic
Background: Analgesics, sedatives, and antipsychotics are commonly prescribed for agitation and delirium in the intensive care unit (ICU), but their use is limited by adverse effects and lack of efficacy. Valproic acid is an alternative treatment option. Objective: The primary objective of this study was to describe valproic acid prescribing in our institution’s ICUs when used for agitation or delirium. Measures of effectiveness and safety were also assessed. Methods: This was a single-center, retrospective, institutional review board–approved cohort study of adult inpatients admitted to the ICU between January 2018 and August 2018. Patients who received valproic acid for the treatment of agitation or delirium for ≥24 hours were included. Prescribing practices were evaluated for dose, frequency, and route of administration. Effectiveness was assessed via agitation and delirium assessment tools and quantity of adjunctive agents used. Results: A total of 80 patients were included, with 35 receiving valproic acid alone and 45 in conjunction with antipsychotics. The most common valproic acid regimen was 250 mg orally 3 times daily. Delirium resolution occurred in 55% of patients: 24 in the valproic acid monotherapy group and 20 in the valproic acid plus antipsychotic group (69% vs 44%; P = 0.03). The incidence of delirium decreased from valproic acid day 0 to day 3 (93% vs 68%; P < 0.01), with no change in agitation (64% vs 63%; P = 0.28). Conclusion and Relevance: Valproic acid is frequently prescribed in agitated, delirious patients at our institution and may have a role in the management of ICU delirium.